JP2024000505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024000505A5 JP2024000505A5 JP2023083545A JP2023083545A JP2024000505A5 JP 2024000505 A5 JP2024000505 A5 JP 2024000505A5 JP 2023083545 A JP2023083545 A JP 2023083545A JP 2023083545 A JP2023083545 A JP 2023083545A JP 2024000505 A5 JP2024000505 A5 JP 2024000505A5
- Authority
- JP
- Japan
- Prior art keywords
- ptx3
- expression
- mir
- vasculitis
- hsa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2023/021641 WO2023248845A1 (ja) | 2022-06-20 | 2023-06-12 | Ｐｔｘ３の発現制御剤；関節リウマチ、自己免疫疾患に伴う血管炎または皮膚硬化の予防薬または治療薬、あるいはそれらの改善方法 |
| EP23827031.8A EP4541359A1 (en) | 2022-06-20 | 2023-06-12 | Ptx3 expression control agent, prophylactic drug or therapeutic drug for vasculitis or hardening of skin associated with rheumatoid arthritis, autoimmune disease, method for improving vasculitis or hardening of skin associated with rheumatoid arthritis, autoimmune disease |
| CN202380046686.5A CN119403562A (zh) | 2022-06-20 | 2023-06-12 | Ptx3表达调控剂；类风湿性关节炎、自身免疫疾病所伴随的血管炎或皮肤硬化的预防药或治疗药，或它们的改善方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022098639 | 2022-06-20 | ||
| JP2022098639 | 2022-06-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024000505A JP2024000505A (ja) | 2024-01-05 |
| JP2024000505A5 true JP2024000505A5 (https=) | 2024-08-08 |
Family
ID=89384628
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023083544A Pending JP2024000504A (ja) | 2022-06-20 | 2023-05-20 | Ｈｍｇｂ１の発現制御剤；急性肺損傷、急性呼吸窮迫症候群または敗血症の予防薬または治療薬、あるいはそれらの改善方法 |
| JP2023083545A Pending JP2024000505A (ja) | 2022-06-20 | 2023-05-20 | Ｐｔｘ３の発現制御剤；関節リウマチ、自己免疫疾患に伴う血管炎または皮膚硬化の予防薬または治療薬、あるいはそれらの改善方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023083544A Pending JP2024000504A (ja) | 2022-06-20 | 2023-05-20 | Ｈｍｇｂ１の発現制御剤；急性肺損傷、急性呼吸窮迫症候群または敗血症の予防薬または治療薬、あるいはそれらの改善方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP2024000504A (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2025170079A1 (https=) * | 2024-02-09 | 2025-08-14 | ||
| WO2025181030A1 (en) * | 2024-02-26 | 2025-09-04 | Fundació Institut D'investigació I Innovació Parc Taulí | Therapy for inflammatory lung diseases |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10709741B2 (en) * | 2013-02-13 | 2020-07-14 | National University Corporation Nagoya University | Composition for preventing or treating inflammatory disease |
-
2023
- 2023-05-20 JP JP2023083544A patent/JP2024000504A/ja active Pending
- 2023-05-20 JP JP2023083545A patent/JP2024000505A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Melamed et al. | Multiple sclerosis and cancer: the ying-yang effect of disease modifying therapies | |
| JP2024000505A5 (https=) | ||
| Morandini et al. | Role of epigenetics in modulation of immune response at the junction of host–pathogen interaction and danger molecule signaling | |
| Ruggieri et al. | Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing–remitting multiple sclerosis | |
| US10787502B2 (en) | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | |
| Mondal et al. | Cinnamon ameliorates experimental allergic encephalomyelitis in mice via regulatory T cells: implications for multiple sclerosis therapy | |
| JP2018520189A5 (https=) | ||
| Licciardi et al. | Immunomodulatory effects of histone deacetylase inhibitors | |
| JP2022188083A5 (https=) | ||
| Nesterova et al. | Anxiolytic activity of diterpene alkaloid songorine | |
| JP6794454B2 (ja) | ランピルナーゼおよび／またはアンフィナーゼを使用するウイルス性結膜炎の処置 | |
| Choe et al. | Melittin inhibits osteoclast formation through the downregulation of the RANKL-RANK signaling pathway and the inhibition of interleukin-1β in murine macrophages | |
| RU2015140572A (ru) | Способы лечения колоректального рака | |
| Suematsu et al. | Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis | |
| JP2016505050A5 (https=) | ||
| Cai et al. | The role of fibroblast-neutrophil crosstalk in the pathogenesis of inflammatory diseases: A multi-tissue perspective | |
| Si et al. | Neuroprotective effect of miR-212-5p on isoflurane-induced cognitive dysfunction by inhibiting neuroinflammation | |
| CN104288168A (zh) | 延龄草苷在制备用于治疗和/或预防小胶质细胞介导的疾病的药物中的用途 | |
| JP2017508737A5 (https=) | ||
| CN103622988A (zh) | 虫草素在制备抗抑郁症的药物中的用途及其制备而得的快速抗抑郁症药物 | |
| Edwards et al. | Histone deacetylase inhibitors and their potential role in inflammatory bowel diseases | |
| Campbell | Will biotechnology stop aging? | |
| CN104434908B (zh) | 山奈酚在抑制受体对器官移植排斥反应药物中的应用 | |
| JPWO2023186806A5 (https=) | ||
| EP4659762A1 (en) | Pharmaceutical composition for preventing and treating hepatic fibrogenesis |